Inicio › Cáncer metastásico › Florida › Tampa
Ensayos clínicos de Cáncer metastásico en Tampa, FL
29 estudios para Cáncer metastásico buscan participantes en centros de Tampa y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
ReclutandoFase 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
ReclutandoFase 1
- Moffitt Cancer Center, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ReclutandoFase 1
- ALX Center 7, Tampa
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
ReclutandoFase 2/3
- Moffitt Cancer Center, Tampa
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
ReclutandoFase 1
- Moffitt Cancer Center, Tampa
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
ReclutandoFase 2
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ReclutandoFase 3
- Florida Cancer Specialists, Tampa
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
ReclutandoFase 1
- Moffitt, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
ReclutandoFase 3
- Moffitt Cancer Center, Tampa
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
ReclutandoFase 3
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
ReclutandoFase 1/2
- Moffitt Cancer Center, Tampa
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
ReclutandoFase 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Moffitt Cancer Center, Tampa
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
ReclutandoFase 3
- Research Site, Tampa
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Investigative Site #128, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
ReclutandoFase 1
- Moffitt Cancer Center, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
ReclutandoFase 3
- Moffitt Cancer Center, Tampa
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Exelixis Clinical Site #8, Tampa
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
ReclutandoFase 3
- Moffitt Cancer Center, Tampa
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
ReclutandoFase 2
- James A. Haley Veterans Administration Hospital, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
ReclutandoFase 1
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
ReclutandoFase 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
ReclutandoFase 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ReclutandoFase 1/2
- Moffitt Cancer Center, Tampa
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
ReclutandoFase 2/3
- Moffitt Cancer Center, Tampa
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
ReclutandoFase 3
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Tampa
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
ReclutandoFase 1
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
Ensayos de Cáncer metastásico en otras ciudades
- Houston, TX104 estudios
- New York City, NY93 estudios
- Nashville, TN70 estudios
- Boston, MA63 estudios
- Los Angeles, CA57 estudios
- St. Louis, MO54 estudios
- Arlington, VA53 estudios
- Philadelphia, PA46 estudios
- Chicago, IL45 estudios
- San Antonio, TX44 estudios
- Washington, DC43 estudios
- Dallas, TX42 estudios
Otros estudios en Tampa
- Cáncer de pulmón de células no pequeñas51 estudios
- Cáncer de seno43 estudios
- Cáncer (todos los tipos)39 estudios
- Cáncer del colon y del recto34 estudios
- Leucemia mielógena aguda29 estudios
- Cáncer de pulmón29 estudios
- Cáncer de páncreas26 estudios
- Cáncer de ovario21 estudios
- Melanoma19 estudios
- Síndromes mielodisplásicos19 estudios
- Cáncer de próstata18 estudios
- Fallo cardíaco18 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.